Cover Image
市場調查報告書

嬰兒痙攣症 (Infantile spasms) :開發中產品分析

Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 362367
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
嬰兒痙攣症 (Infantile spasms) :開發中產品分析 Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 55 Pages
簡介

本報告提供嬰兒痙攣症 (Infantile spasms) 治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

嬰兒痙攣症 (Infantile spasms)的概要

治療藥的開發

  • 開發中產品的概要

嬰兒痙攣症 (Infantile spasms):企業開發中的治療藥

嬰兒痙攣症 (Infantile spasms):開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

嬰兒痙攣症 (Infantile spasms):企業開發中的產品

嬰兒痙攣症 (Infantile spasms的)治療藥的開發企業

  • Anavex Life Sciences Corp.
  • Catalyst Pharmaceuticals, Inc.
  • INSYS Therapeutics, Inc.
  • Novartis AG
  • Retrophin Inc.

嬰兒痙攣症 (Infantile spasms):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

嬰兒痙攣症 (Infantile spasms):最近的開發平台趨勢

嬰兒痙攣症 (Infantile spasms):暫停中的計劃

嬰兒痙攣症 (Infantile spasms):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8152IDB

Summary

Global Markets Direct's, 'Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016', provides an overview of the Infantile Spasm (West Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome)
  • The report reviews pipeline therapeutics for Infantile Spasm (West Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Infantile Spasm (West Syndrome) therapeutics and enlists all their major and minor projects
  • The report assesses Infantile Spasm (West Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Infantile Spasm (West Syndrome)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Infantile Spasm (West Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Infantile Spasm (West Syndrome) Overview
  • Therapeutics Development
    • Pipeline Products for Infantile Spasm (West Syndrome) - Overview
  • Infantile Spasm (West Syndrome) - Therapeutics under Development by Companies
  • Infantile Spasm (West Syndrome) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Infantile Spasm (West Syndrome) - Products under Development by Companies
  • Infantile Spasm (West Syndrome) - Companies Involved in Therapeutics Development
    • Anavex Life Sciences Corp.
    • Catalyst Pharmaceuticals, Inc.
    • INSYS Therapeutics, Inc.
    • Novartis AG
    • Retrophin Inc.
  • Infantile Spasm (West Syndrome) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANAVEX-273 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVL-5189 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cosyntropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cosyntropin ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CPP-115 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Infantile Spasm (West Syndrome) - Recent Pipeline Updates
  • Infantile Spasm (West Syndrome) - Dormant Projects
  • Infantile Spasm (West Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
      • Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD
      • Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115
      • Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms
      • Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115
      • Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
      • Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia
      • Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome
      • Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference
      • Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Infantile Spasm (West Syndrome), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Catalyst Pharmaceuticals, Inc., H1 2016
  • Infantile Spasm (West Syndrome) - Pipeline by INSYS Therapeutics, Inc., H1 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Novartis AG, H1 2016
  • Infantile Spasm (West Syndrome) - Pipeline by Retrophin Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Infantile Spasm (West Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016
  • Infantile Spasm (West Syndrome) - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Infantile Spasm (West Syndrome), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top